Kyntra Bio
| Company type | Public |
|---|---|
| Nasdaq: KYNB | |
| Industry | Biotechnology |
| Founded | 1993 |
| Founder | Thomas B. Neff |
| Headquarters | Virtual office address: 350 Bay Street, Suite 100 #6009, |
Key people |
|
Number of employees | 52 (United States, December 2024) |
| Website | kyntrabio |
Kyntra Bio, Inc. (formerly FibroGen, Inc.) is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate.
On January 8, 2026, FibroGen changed its name to Kyntra Bio and ticker symbol to KYNB.